Baxter International (NYSE: BAX) recently received a number of ratings updates from brokerages and research firms:

  • 10/16/2017 – Baxter International was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company rides on the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals. However, lower cyclophosphamide sales in the coming quarters might mar the Baxter’s bottom line. Of the major positives, a favorable product mix, stringent cost control and expanding operating margin are notable. Baxter reported impressive results in the second quarter, driven by favorable tidings on the regulatory front, strategic partnerships and product launches. The company recently completed the acquisition of Claris Injectables. Solid U.S. sales of IV therapies, IV access sets, select anesthesia and critical care products are key catalysts at the moment. On the flipside, a strong U.S. dollar, intensifying competition and lackluster sales growth are key concerns at the moment.”
  • 10/15/2017 – Baxter International was given a new $68.00 price target on by analysts at Cowen and Company. They now have a “hold” rating on the stock.
  • 10/13/2017 – Baxter International had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $70.00 price target on the stock.
  • 10/13/2017 – Baxter International had its “neutral” rating reaffirmed by analysts at Cowen and Company.
  • 10/10/2017 – Baxter International was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $69.00 price target on the stock. According to Zacks, “Over the past year, Baxter has outperformed the broader industry in terms of price performance. The company rides on the recent launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals. However, lower cyclophosphamide sales in the coming quarters might mar the Baxter’s bottom line. Of the major positives, a favorable product mix, stringent cost control and expanding operating margin are notable. Baxter reported impressive results in the second quarter, driven by favorable tidings on the regulatory front, strategic partnerships and product launches. The company recently completed the acquisition of Claris Injectables. Solid U.S. sales of IV therapies, IV access sets, select anesthesia and critical care products are key catalysts at the moment. On the flipside, a strong U.S. dollar, intensifying competition and lackluster sales growth are key concerns at the moment.”
  • 10/3/2017 – Baxter International had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $60.00 price target on the stock.
  • 9/1/2017 – Baxter International had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $60.00 price target on the stock.

Baxter International Inc. (NYSE:BAX) opened at 63.92 on Wednesday. The stock has a market cap of $34.83 billion, a price-to-earnings ratio of 38.79 and a beta of 0.65. Baxter International Inc. has a 12 month low of $43.13 and a 12 month high of $64.75. The stock’s 50 day moving average price is $62.89 and its 200-day moving average price is $59.41.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.06. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The firm had revenue of $2.61 billion for the quarter, compared to the consensus estimate of $2.59 billion. During the same period in the previous year, the business earned $0.46 earnings per share. The company’s revenue for the quarter was up .8% compared to the same quarter last year. Equities research analysts predict that Baxter International Inc. will post $2.39 EPS for the current year.

In related news, Director Thomas T. Stallkamp sold 8,920 shares of Baxter International stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $62.28, for a total value of $555,537.60. Following the sale, the director now directly owns 16,263 shares in the company, valued at $1,012,859.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Giuseppe Accogli sold 12,670 shares of Baxter International stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $60.96, for a total value of $772,363.20. Following the completion of the sale, the senior vice president now owns 33,286 shares in the company, valued at $2,029,114.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,050 shares of company stock worth $2,158,587. Company insiders own 0.05% of the company’s stock.

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Receive News & Ratings for Baxter International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.